On ECHEMI
Home > Drugs > Mediastinal tumors
Mediastinal tumors
The mediastinum is located between the lungs on both sides, with the sternum and thoracic vertebrae as its front and back boundaries. There are many important organs in it, including large blood vessels, trachea, main bronchi, pericardium, esophagus, thymus, and a large amount of fat, nerves, lymphatic vessels and other tissues. Due to abnormal congenital development or acquired cysts or tumor formation, it becomes a mediastinal tumor. There are many types of tumors in the mediastinum, some are primary and some are metastatic. Benign primary tumors are more common, but a considerable number of them are malignant. In order to indicate the location of the lesion in the mediastinum, the mediastinum can be divided into several parts, divided into upper and lower parts at the level of the sternum and the lower edge of the fourth thoracic vertebra. The mediastinal space containing many important organs is called the "visceral organ mediastinum" (middle mediastinum), the space in front of the right trachea and pericardium is the anterior mediastinum; the space behind the trachea and pericardium (including the esophagus and paraspinal mediastinum) is called the posterior mediastinum. According to domestic statistics, neurogenic tumors rank first in the incidence of mediastinal tumors, followed by teratogenic tumors, thymic tumors and thyroid tumors, and various cystic tumors are the least common.
  • Site of disease:

    Mediastinum
  • Infectious :

    Not contagious
  • Frequent population:

    All groups
  • Related symptoms:

    chest pain facial edema dysphagia chest pain chest tightness
  • Concurrent disease:

Related Drugs
Fludarabine phosphate
Indication: For the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not improved or has progressed during or after treatment with at least one standard alkylating agent-containing regimen.
Manufacturer:

Nanjing Hairun Pharmaceutical Co., Ltd.

Fludarabine Phosphate for Injection
Indication: For the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not improved or has progressed during or after treatment with at least one standard alkylating agent-containing regimen.
Pingxiao tablets
Manufacturer:

Ningxia Goldsun MEDICAL Co., Ltd.

Anti-cancer Ping Wan
Manufacturer:

Jiangsu Kanion Pharmaceutical Co., Ltd.

Antico Capsules
Manufacturer:

Changchun Haiwang Biological Pharmaceutical Co., Ltd.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.